Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NT-112: Autologous, engineered T Cells targeting KRAS G12DOngoingOpen NCT06218914 on ClinicalTrials.gov ↗
Population
Loading…
Intervention
Loading…
Comparator
Loading…
Loading…